Mamatha Pasnoor, MD
Neurology · Kansas City, KSNPI 1437352820
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $55,181 of the $86,240 with a category attached, or 64.0%. 17 manufacturers reported payments, led by Argenx US, Inc. at 24.2% of the total. Reporting peaked in 2024 at $28,489 and has fallen 51.8% since, to $13,727 in 2025. Among neurology clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 121 payments — averaging $712.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Argenx US, Inc.$21K
- Takeda Pharmaceuticals U.S.A., Inc.$14K
- Grifols USA, LLC$10K
- Janssen Global Services, LLC$9K
- CSL Behring$8K
- Amgen$7K
- plus $17K from 11 others
Across 656 payments — averaging $5833.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$2.4M
- Argenx US, Inc.$744K
- Sanofi US Services Inc.$237K
- Takeda Pharmaceuticals U.S.A., Inc.$121K
- Catalyst Pharmaceuticals, Inc.$72K
- Amgen$60K
- plus $157K from 8 others
What the payments were for
- Consulting fees$55,18164%
- Speaking & faculty fees$21,04024%
- Travel & lodging$7,1668%
- Food & beverage$2,7543%
- Education$990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Argenx US, Inc. | 30 | $20,863 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $14,300 |
| Grifols USA, LLC | 5 | $9,949 |
| Janssen Global Services, LLC | 13 | $9,306 |
| CSL Behring | 15 | $7,865 |
| Amgen | 6 | $7,101 |
| Catalyst Pharmaceuticals, Inc. | 7 | $5,254 |
| UCB SA | 2 | $4,030 |
| AstraZeneca(2 entities) | 10 | $3,951 |
| Janssen Scientific Affairs, LLC | 1 | $2,250 |
| Octapharma USA, Inc. | 1 | $1,000 |
| Hospira, Inc. | 11 | $180 |
| Johnson & Johnson | 1 | $99 |
| Alnylam Pharmaceuticals Inc. | 2 | $31 |
| Bio Products Laboratory USA, Inc. | 2 | $30 |
| GRT US Holding, Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$86,240 in reported general payments places this provider in the 90th percentile of 131 neurology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvgartEfgartigimod Alfa-Fcab | 42 | $2,233,788 |
| UltomirisRavulizumab-Cwvz | 29 | $1,866,472 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 42 | $506,972 |
| ZilbrysqZilucoplan Sodium | 12 | $504,836 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 72 | $432,799 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 49 | $277,687 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 19 | $242,934 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 23 | $102,258 |
| Pyridostigmine Bromide | 262 | $31,226 |
| Mycophenolate Mofetil | 51 | $8,696 |
| Azathioprine | 74 | $5,890 |
| Gabapentin | 87 | $3,666 |
| Pregabalin | 67 | $3,356 |
| Prednisone | 286 | $2,609 |
| MethotrexateMethotrexate Sodium | 90 | $2,093 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Argenx US, Inc.Vyvgart | $20,863 | $2,233,78842 claims |
| AstraZenecaUltomiris | $3,951 | $1,866,47229 claims |
| Grifols USA, LLCGamunex-C | $9,949 | $432,79972 claims |
| CSL BehringPrivigen | $7,865 | $277,68749 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $14,300 | $102,25823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 131 neurology providers in Kansas.
Other neurology in Kansas City
- Ivan OsorioKansas City$101.7M
- Rajesh PahwaKansas City$889K
- Richard DubinskyKansas City$122K
- Jeffrey BurnsKansas City$115K
- Amanda ThuringerKansas City$87K
- Michael AbrahamKansas City$48K
- Constantine FarmakidisKansas City$25K
- Andrew CreedKansas City$16K
- James AppelbaumKansas City$15K
- Patrick LandazuriKansas City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.